Core Insights - Longleaf Partners Small-Cap Fund reported a return of 2.03% in Q3 2025, underperforming compared to the Russell 3000's 8.18% and the Russell 2000's 12.39% [1] - Oscar Health, Inc. (NYSE:OSCR) experienced a one-month return of -2.97% and a 52-week decline of 7.45%, closing at $16.65 per share with a market capitalization of $4.794 billion on December 1, 2025 [2][3] Fund Performance - The Longleaf Partners Small-Cap Fund's performance in Q3 2025 was significantly lower than major indices, indicating challenges in stock selection or market conditions [1] Oscar Health, Inc. Analysis - Oscar Health transitioned from being a contributor to a detractor in the fund's performance, with claims losses in the healthcare sector being worse than expected [3] - The fund sold its remaining position in Oscar Health as the price-to-value gap closed, marking the investment as successful despite the volatility [3] - Oscar Health reported approximately $3 billion in revenue for Q3 2025, reflecting a 23% year-over-year increase [4] Hedge Fund Interest - Oscar Health was held by 40 hedge fund portfolios at the end of Q3 2025, a decrease from 43 in the previous quarter, indicating a decline in popularity among hedge funds [4] Investment Outlook - While Oscar Health shows potential, the fund suggests that certain AI stocks may offer better upside potential with less downside risk [4]

Core Viewpoint - Spectral AI Inc. is raising $7.6 million to enhance its balance sheet and support the development of its DeepView System, aiming for commercial readiness by 2026 [1][2][3]. Group 1: Capital Raise Details - The company plans to issue 4 million shares of common stock at a price of $1.90 per share, along with corresponding warrants priced at $2.51 per share [2]. - The capital raised will facilitate the expansion of clinical indications for the DeepView System [2][3]. Group 2: Company Overview - Spectral AI Inc. specializes in medical diagnostics using AI and multispectral imaging to evaluate wound healing potential [4]. - The technology developed by the company aids clinicians in making quicker and more accurate treatment decisions for patients suffering from burns and diabetic foot ulcers [4]. Group 3: Strategic Commitment - The company remains committed to its current BARDA Project BioShield (PBS) contract while advancing its AI technology to enhance product offerings [3].

Core Insights - The article discusses the 13 best AI stocks to buy under $20, highlighting the significant role of artificial intelligence in investment strategies over the past two years, contributing to record highs in the equity market [1] - Concerns about an AI bubble are rising, with experts suggesting the need for diversification into stocks trading at discounted valuations [3][4] - A Bank of America survey indicates that a third of fund managers view the AI bubble as a major risk, yet this has not significantly dampened overall positive market sentiment [4][5] Industry Overview - The AI sector has been a driving force behind the recent equity market rally, with major tech companies significantly influencing the S&P 500 index [1] - The AI boom has led to historical highs in stock valuations, prompting investors to reconsider their strategies [2] - The concept of a "rational bubble" has been introduced, suggesting that while there are opportunities, only a few companies will emerge as winners [3] Company Insights - **Veritone Inc. (NASDAQ:VERI)**: - Current share price is $6.14, with a 180% increase over the past six months [9] - Analysts at Needham initiated coverage with a 'Buy' rating and a $10 price target, expecting continued outperformance driven by growth in its aiWARE platform and other market opportunities [10][11][12] - **Spectral AI Inc. (NASDAQ:MDAI)**: - Current share price is $2.22, with 7 hedge fund holders [13] - The company announced a $7.6 million offering to support the expansion of its DeepView System, which is aimed at enhancing clinical indications and preparing for commercial readiness in 2026 [13][14][15] - Spectral AI utilizes AI and multispectral imaging for medical diagnostics, particularly in assessing wound healing potential [16]

Core Insights - The article highlights the rapid growth of artificial intelligence (AI) in the healthcare sector, with significant advancements in AI applications for medical purposes [1][2][8] - Avant Technologies, Inc. is positioned as a key player in AI-driven healthcare innovation, particularly through its partnership with Ainnova Tech and the development of the Vision AI platform [3][5][8] AI in Healthcare - Dartmouth researchers conducted a clinical trial of a therapy chatbot powered by generative AI, showing significant symptom improvements in participants [1] - Bill Gates predicts that AI will democratize medical advice, making it free and widely accessible [2] - Layer Health raised $21 million to address scalability challenges in healthcare AI, indicating strong investor interest in this sector [2] Avant Technologies and Ainnova - Avant Technologies and Ainnova Tech are collaborating to present at the 2025 Healthcare Innovation Summit in Mexico City, focusing on digital transformation in healthcare [3][5] - Ainnova's CEO will discuss the impact of the Vision AI platform on early disease detection, with clinical trial protocols being designed for FDA submission [4][6] - The Vision AI platform has received commercial clearance in Brazil and is preparing for clinical pilots across the Americas [5] Regulatory and Market Position - Ainnova is working with global CRO Fortrea to seek FDA 510(k) clearance for Vision AI in detecting diabetic retinopathy, which could expand its use in chronic disease management [6][8] - Avant Technologies and Ainnova jointly control Ai-nova Acquisition Corp., which holds global licensing rights to a technology portfolio validated on over 2.3 million clinical data points [7] Other Industry Developments - Apple Inc. is developing an AI-driven health coach, potentially enhancing its Health app with features for diet and exercise guidance [9][10][11] - Amazon.com, Inc. is testing a health assistant chatbot called Health AI, which aims to provide medical guidance and connect users to its online pharmacy [12][13] - Spectral AI, Inc. reported strong results from its DeepView® System in a Burn Validation Study, aiming for FDA submission by mid-2025 [14][15] - GE HealthCare Technologies Inc. launched the Revolution™ Vibe CT system, featuring AI-powered cardiac imaging to improve diagnostic speed and patient comfort [16][17]